A5084347846- Radiopharmaceutical Chemistry and Applications
- Nuclear Physics and Applications
- Medical Imaging Techniques and Applications
- Radioactive element chemistry and processing
- Chemical Synthesis and Characterization
- Radiation Therapy and Dosimetry
- Nuclear reactor physics and engineering
- Boron Compounds in Chemistry
- Medical Imaging and Pathology Studies
- Nuclear Materials and Properties
- Particle accelerators and beam dynamics
- Radiation Detection and Scintillator Technologies
- Graphite, nuclear technology, radiation studies
- Radioactive Decay and Measurement Techniques
- Superconducting Materials and Applications
- Radioactive contamination and transfer
- Superconductivity in MgB2 and Alloys
- Superconducting and THz Device Technology
- Radioactivity and Radon Measurements
- Nuclear physics research studies
- Extraction and Separation Processes
- Chemical Reactions and Isotopes
- Advanced Radiotherapy Techniques
- Monoclonal and Polyclonal Antibodies Research
- Lanthanide and Transition Metal Complexes
Los Alamos National Laboratory
2014-2024
Los Alamos Medical Center
2018
International Isotopes (United States)
2012
iThemba Laboratory
1999-2001
Forschungszentrum Jülich
1994-1999
A new method has been developed for the isolation of 223,224,225Ra, in high yield and purity, from a proton irradiated 232Th matrix. Herein we report an all-aqueous process using multiple solid-supported adsorption steps including citrate chelation to remove >99.9% barium contaminants by activity final radium product. procedure involving use three columns succession was developed, separation 223,224,225Ra thorium matrix obtained with overall recovery 91 ± 3%, average radiochemical purity...
Nuclear formation cross sections are reported for 65 nuclides produced from 800-MeV proton irradiation of thorium foils. These data useful as benchmarks computational predictions in the ongoing process theoretical code development and also design spallation-based radioisotope production currently being considered multiple radiotherapeutic pharmaceutical agents. Measured compared with three mcnp6 event generators used to evaluate potential productions radioisotopes interest medical...
One of the main challenges in targeted alpha therapy is assuring delivery α‐particle dose to cells. Thus, it critical identify ligands for α‐emitting radiometals that will form complexes are very stable, both vitro and vivo. In this investigation, thorium‐227 ( t 1/2 = 18.70 days) chelation containing hydroxypyridinonate (HOPO) or picolinic acid (pa) moieties stability resultant were studied. Chelation reactions followed by reversed‐phased HPLC gamma spectroscopy. Studies revealed high 227...
Abstract Background 44 Sc/ 47 Sc is an attractive theranostic pair for targeted in vivo positron emission tomographic (PET) imaging and beta-particle treatment of cancer. The Ti/ generator allows daily onsite production this diagnostic isotope, which may provide alternative PET facilities that lack in-house irradiation capabilities. Early animal patient studies have demonstrated the utility Sc. In our current study, we built evaluated a novel clinical-scale generator, explored...
Abstract Rhenium-186g ( T 1/2 = 89.2 h) is a β − emitter suitable for therapeutic applications. Current production methods rely on reactor via 185 Re( n , γ ) which results in low specific activities, thereby limiting its use. Production by p d activation of enriched 186 W 186g Re product with higher activity, allowing it to be used targeted therapy limited receptors. A test target consisting pressed, sintered nat WO 3 was proton irradiated at Los Alamos (LANL-IPF) evaluate yield and...
Abstract Accelerator production of 225 Ac addresses the global supply deficiency currently inhibiting clinical trials from establishing Ac's therapeutic utility, provided that accelerator product is sufficient radionuclidic purity for patient use. Two proton activation experiments utilizing stacked foil technique between 40 and 200 MeV were employed to study likely co-formation radionuclides expected be especially challenging separate Ac. Foils assayed by nondestructive γ -spectroscopy α...
Abstract Targeted alpha therapy (TAT) is a treatment method of increasing interest to the clinical oncology community that utilizes α -emitting radionuclides conjugated biomolecules for selective killing tumor cells. Proton irradiation thorium generates number with therapeutic potential application via TAT. In particular, radionuclide 230 Pa formed 232 Th( p , 3 n ) nuclear reaction and partially decays U, an emitter which has recently received attention as possible nuclide. this study, we...
Protactinium-230 (t1/2 = 17.4 d) is the parent isotope of 230U 20.8 d), a radionuclide interest for targeted alpha therapy (TAT). Column chromatographic methods have been developed to separate no-carrier-added 230Pa from proton irradiated thorium targets and accompanying fission products. Results reported within demonstrate use novel sulfur bearing extraction resins selective separation protactinium. The recovery yield was 93 ± 4% employing R3P═S type commercially available resin 88 DGTA...
Grafting of DGA on mesoporous silica affords a sorbent with the potential to separate U from Pa and Th.